Pembrolizumab is known under the following name: Keytruda.
|
|
- Christiana Morgan
- 5 years ago
- Views:
Transcription
1 KEYTRUDA AS A THERAPY FOR MELANOMA IN ADVANCED STAGE OR THAT CANNOT BE EXTIRPATED AND NON-SMALL CELL LUNG CANCER IN ADVANCED STAGE. Section Medicine Subsection Introduction Medicine Original Date February 19, 2016 Revision Date November 04, 2016 "This policy is protected by copyright under federal laws and/or intellectual property laws and State regulations. No part of this publication may be reproduced, stored in a retrieval system, transmitted in any form or by any medium, either electronic, mechanical, photocopy, recording or any other, without the written permission of the health plan." Definition Pembrolizumab is known under the following name: Keytruda. The NCCN in its latest version (2.2016) for Melanoma guidelines details that Keytruda is included as a first line of treatment for patients in advanced stages. Guidelines for Non- Small Cell Lung Cancer, from this same organization in its latest version (4.2016) details that Keytruda is included as subsequent treatment for patients in advanced stages and that the tumor expresses the PD-L1 protein. The organization explained that in recent studies Keytruda shows greater efficacy and better security compared with other treatments. Background The Food and Drug Administration (FDA) granted Keytruda the designation of revolutionary therapy because preliminary clinical studies showed that this drug can offer a substantial improvement of the condition in comparison with the other available therapies. In addition, it received the designation of orphan drug (a drug for the treatment of rare or unusual conditions) and of priority assessment. This category is granted to drugs that, at the time of submitting the application, have the potential to represent a significant Page 1 of 7
2 improvement in safety or efficacy in the treatment of a serious disease. The FDA decided to approve this drug based in the Accelerated Approval Program, which allows to approve a drug to treat a serious or potentially deadly disease based in clinical data that show that there is a therapeutic benefit for the patients. It provides immediate access to these new drugs, while simultaneously the company continues performing clinical studies. Advanced Melanoma Melanoma represents approximately 5% of all new cases of cancer in the United States. It is the most dangerous form of skin cancer that develops by damage in the DNA of the skin cells causing mutations that produce a rapid cell multiplication and the formation of malignant tumors. These tumors are produced in the melanocytes (skin pigment-producing cells, melanin), located in the basal membrane of the epidermis. According to the American Cancer Society, it is estimated that more than 120,000 new cases of melanoma are diagnosed in a year and that about 9,710 patients die annually from this disease. This type of cancer if it is not identified or treated in time it can spread to other cells of the body becoming metastatic melanoma. Advanced Non-Small Cell Lung Cancer Lung cancer is the biggest cause of death by cancer in the United States. About 85-90% of cancerous tumors in the lung are diagnosed as Non-Small Cell lung cancer, due to their size. This is developed by damage to the DNA in the cells of the lining of the bronchi or other structures of the lung such as bronchioles and alveoli. This genetic damage causes mutations in the cells, generates an accelerated cell multiplication and growth of malignant tumors. According to the American Cancer Society, it is estimated that more than 221,200 new cases are diagnosed in a year and that approximately 158,040 patients die because of this disease annually. If this type of cancer is not identified or treated in time it can spread to other cells of the body becoming the metastatic Non-Small Cell lung cancer. Page 2 of 7
3 Regulatory Situation Advanced Melanoma The FDA approved Keytruda to treat melanoma that is advanced or that cannot be extirpated. The efficacy of Keytruda was established in 834 participants of a clinical trial with melanoma patients in advanced or inoperable stage and whose disease progressed after receiving at least 1 previous treatment. Those patients had not received ipilimumab previously. The participants in the study were treated with Keytruda, at a dose of 10 milligrams per kilogram (mg/kg) every 3 weeks, Keytruda 10 milligrams per kilogram (mg/kg) every 2 weeks or ipilimumab 3 milligrams per kilogram (mg/kg) every 3 weeks for 4 doses. Participants receiving the dose of 10 mg/kg every 3 weeks showed a reduction in the size of their tumors in approximately 33% of the cases. This effect lasted at least 1.4 to 8.1 months, and in the majority of patients continued after this period. The safety of Keytruda was evaluated in 411 participants with advanced stage melanoma. The most common side effects reported were fatigue, cough, nausea, diarrhea, constipation, decreased appetite, skin itching, rash and pain in joints (arthralgia). The Keytruda can also cause severe side effects associated with immunological reactions or related to rare damage to healthy organs (such as the lungs, colon, liver, hormoneproducing glands). Advanced Non-Small Cell Lung Cancer The FDA approved Keytruda to treat Non-Small Cell lung cancer in advanced stage in patients who after receiving other treatments their condition has progressed and they express the PD-L1 protein. The efficacy of Keytruda was established in a subset of 61 patients participating in a clinical study suffering from Non-Small Cell lung cancer in advanced stage and whose disease progressed after receiving chemotherapy with a Platinum or any targeted therapy for certain genetic mutations (ALK or EGFR). In addition, these participants presented tumors positive to the protein PD-L1 based on the result of the diagnostic test approved by the FDA (22C3 pharmdx). The participants were treated with Keytruda with a higher Page 3 of 7
4 dosage than the one recommended, 10 milligrams per kilogram (mg/kg) every 2-3 weeks. Approximately 41% of participants noted a reduction in the size of their tumors. This effect lasted at least 2.1 to 9.1 months. The safety of Keytruda was evaluated in 550 participants with Non-Small Cell lung cancer in advanced stage. The most common side effects reported were fatigue, cough, decrease in appetite and lack of air. The Keytruda can also cause severe side effects associated with immunological reactions or related to rare damage to healthy organs (such as the lungs, colon, hormone-producing glands). Policy A. Keytruda is indicated to treat advanced, metastatic and inoperable melanoma and Non-Small Cell lung cancer in advanced stage that progresses after having received other treatments and presents tumors that express the PD-L1 protein. 1. The FDA approved dose is 2 mg/kg in intravenous infusion (IV) for 30 minutes. It should be given once every three weeks. The treatment must continue until the progression of the disease occurs or unacceptable toxicity. 2. In pharmacokinetic studies no difference was found in creatinine clearance (CrCl) of patients with mild, moderate or severe renal dysfunction, (egfr 15 ml/min to 89 ml/min) compared with patients of normal renal function (egfr 90 ml/min); patients with egfr < 15 ml/min were not studied. Therefore, no adjustment of dosage in patients with renal dysfunction is required. B. The decision to treat a patient with Keytruda should be based on the following criteria: 1. It must be prescribed by a hematologist or oncologist. 2. Diagnosis of advanced or that cannot be extirpated melanoma or Non-Small Cell lung cancer in advanced stage that progresses after having received other treatments and presents tumor(s) that express the PD-L1 protein. 3. Patient 18 years or older Page 4 of 7
5 4. Required information: a) Patient s weight b) Evidence of having received chemotherapy with a platinum (cisplatin or carboplatin) c) It presents evidence of having obtained a positive result to the expression of the PD-L1 protein (determined by the test approved by the FDA). C. The admission of the patient to the hospital with the single and only purpose of administering Keytruda requires individual pre-authorization for treatment in essence of service. The request must include the following documentation: 1. Insured s contract number. 2. It must be prescribed by a hematologist or oncologist. 3. ICD-9 or ICD-10 diagnostic code. 4. Medical necessity documentation. a. Evidence of at least one metastasis 5. Number of milligrams to be administered (2 mg/kg) D. If a patient, with the diagnosis approved for payment by this policy, is admitted to the hospital, and as part of the treatment requires the use of Keytruda, Triple-S will cover the treatment after the requirements previously exposed are met. E. Triple-S only pays the dose every 3 weeks of the medication. F. Triple-S will not consider for payment the use of Keytruda under the following circumstances: a. The patient presents hypersensitivity to the product or any of its components. b. Patient does not comply with any of the above mentioned criteria. Page 5 of 7
6 Codes Melanoma Code Number Description ICD Malignant melanoma of the skin ICD 10 C43 Malignant melanoma of the skin ICD Non-Small Cell Lung Cancer ICD 10 C34 Non-Small Cell Lung Cancer HCPCS J9271 Injection, pembrolizumab 1 mg Limitation According to those established in policy. Pre-Auto Required Ángela Hernández, MD Associate Medical Director Benjamín Santiago, MD Executive Medical Director References 1. American Cancer Society. Cancer Facts & Figures Accessed January 11, Codes ICD-9 and ICD-10 for malignant melanoma: ICD-9-CM to ICD-10-CM Based on FY2014 ICD-9-CM codes Recovered from: 3. Facts & Comparisons eanswers Keytruda Monograph. Last modification October Wolters Kluwer Health, Inc. Recovered from: Page 6 of 7
7 apping=-1&fromtop=true#firstmatch 4. Facts & Comparisons eanswers Keytruda Monograph. Last modification October Recovered from: Keytruda (pembrolizumab) [prescribing information]. Whitehouse Station, NJ: Merck; September Merck Sharp and Dohme Co Highlights of Prescribing Information. Recovered from: 7. National Comprehensive Cancer Network (NCCN) Guidelines Melanoma Version Available at: Accessed on January, National Comprehensive Cancer Network (NCCN) Guidelines Non-Small Cell Lung Cancer Version Available at: Accessed on January, Skin Cancer Foundation Melanoma. Recovered from: UptoDate Pembrolizumab Drug Information. 11. U.S Food and Drug Administration FDA approves Keytruda for advanced melanoma. First PD-1 blocking drug to receive agency approval. Recovered from: U.S Food and Drug Administration FDA approves Keytruda for advanced non-small cell lung cancer. First drug approved in lung cancer for patients whose tumors express PD-L1. Recovered from: Page 7 of 7
Clinical Policy: Pembrolizumab (Keytruda) Reference Number: CP.PHAR.322
Clinical Policy: (Keytruda) Reference Number: CP.PHAR.322 Effective Date: 03/17 Last Review Date: 03/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationKeytruda. Keytruda (pembrolizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 6 Last Review Date: September 15, 2017 Keytruda Description Keytruda
More informationKeytruda. Keytruda (pembrolizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 5 Last Review Date: June 24, 2016 Keytruda Description Keytruda (pembrolizumab)
More informationKeytruda. Keytruda (pembrolizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 9 Last Review Date: September 20, 2018 Keytruda Description Keytruda
More informationKeytruda. Keytruda (pembrolizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 9 Last Review Date: November 30, 2018 Keytruda Description Keytruda
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Imfinzi) Reference Number: CP.PHAR.339 Effective Date: 07.01.17 Last Review Date: 05.18 Line of Business: Medicaid, HIM-Medical Benefit Coding Implications Revision Log See Important
More informationKeytruda. Keytruda (pembrolizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 7 Last Review Date: December 8, 2017 Keytruda Description Keytruda
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Ipilimumab (Yervoy) Reference Number: CP.PHAR.319 Effective Date: 10.01.18 Last Review Date: 07.13.18 Line of Business: Oregon Health Plan Coding Implications Revision Log See Important
More informationClinical Policy: Nivolumab (Opdivo) Reference Number: CP.HNMC.27 Effective Date: Last Review Date: Line of Business: Medicaid - HNMC
Clinical Policy: (Opdivo) Reference Number: CP.HNMC.27 Effective Date: 07.01.17 Last Review Date: 02.18 Line of Business: Medicaid - HNMC Revision Log See Important Reminder at the end of this policy for
More informationClinical Policy: Nivolumab (Opdivo) Reference Number: CP.PHAR.121 Effective Date: Last Review Date: Line of Business: Medicaid
Clinical Policy: (Opdivo) Reference Number: CP.PHAR.121 Effective Date: 07.15 Last Review Date: 01.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationImmunotherapy in Lung Cancer
Immunotherapy in Lung Cancer Jamie Poust Pharm. D., BCOP Oncology Pharmacist University of Colorado Hospital Objectives Describe the recent advances in immunotherapy for patients with lung cancer Outline
More informationClinical Policy: Nivolumab (Opdivo) Reference Number: CP.PHAR.121
Clinical Policy: (Opdivo) Reference Number: CP.PHAR.121 Effective Date: 07/15 Last Review Date: 04/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationClinical Policy: Atezolizumab (Tecentriq) Reference Number: CP.PHAR.235 Effective Date: 06/16 Last Review Date: 05/17
Clinical Policy: (Tecentriq) Reference Number: CP.PHAR.235 Effective Date: 06/16 Last Review Date: 05/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important
More informationClinical Policy: Nivolumab (Opdivo) Reference Number: ERX.SPA.302 Effective Date:
Clinical Policy: (Opdivo) Reference Number: ERX.SPA.302 Effective Date: 03.01.19 Last Review Date: 02.19 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationOpdivo. Opdivo (nivolumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.53 Subsection: Antineoplastic Agents Original Policy Date: January 16, 2015 Subject: Opdivo Page:
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Abraxane) Reference Number: CP.PHAR.176 Effective Date: 07.01.15 Last Review Date: 05.18 Line of Business: HIM, Medicaid Coding Implications Revision Log See Important Reminder at the
More informationClinical Policy: Ramucirumab (Cyramza) Reference Number: CP.PHAR.119
Clinical Policy: (Cyramza) Reference Number: CP.PHAR.119 Effective Date: 05/15 Last Review Date: 04/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationClinical Policy: Topotecan (Hycamtin) Reference Number: CP.PHAR.64 Effective Date: Last Review Date: Line of Business: Medicaid, HIM
Clinical Policy: (Hycamtin) Reference Number: CP.PHAR.64 Effective Date: 06.01.11 Last Review Date: 05.18 Line of Business: Medicaid, HIM Coding Implications Revision Log See Important Reminder at the
More informationKeytruda (pembrolizumab)
Keytruda (pembrolizumab) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 10/01/2015 Current Effective Date: 07/24/2017TBD03/01/2018 POLICY A. INDICATIONS The
More informationPolicy. Medical Policy Manual Approved Revised: Do Not Implement until 6/30/2019. Nivolumab
Medical Manual Approved Revised: Do Not Implement until 6/30/2019 Nivolumab NDC CODE(S) 00003-3772-XX Opdivo 40 MG/4ML SOLN (B-M SQUIBB U.S. (PRIMARY CARE)) 00003-3774-XX Opdivo 100 MG/10ML SOLN (B-M SQUIBB
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Trastuzumab (Herceptin), Trastuzumab-dkst (Ogivri) Reference Number: CP.PHAR.228 Effective Date: 07.01.18 Last Review Date: 05.18 Line of Business: Oregon Health Plan Coding Implications
More informationKEYTRUDA is also indicated in combination with pemetrexed and platinum chemotherapy for the
FDA-Approved Indication for KEYTRUDA (pembrolizumab) in Combination With Carboplatin and Either Paclitaxel or Nab-paclitaxel for the Firstline Treatment of Patients With Metastatic Squamous Non Small Cell
More informationsystem to help fight cancer Working with your immune
KEYTRUDA Working with your immune system to help fight cancer www.fightcancer.co.nz CONTACT DETAILS Your Oncologist/Specialist ABOUT About KEYTRUDA How KEYTRUDA works Name How KEYTRUDA works with your
More informationClinical Policy: Ramucirumab (Cyramza) Reference Number: CP.HNMC.09 Effective Date: Last Review Date: Line of Business: Medicaid - HNMC
Clinical Policy: (Cyramza) Reference Number: CP.HNMC.09 Effective Date: 07.01.17 Last Review Date: 02.18 Line of Business: Medicaid - HNMC Revision Log See Important Reminder at the end of this policy
More informationsystem to help fight cancer Working with your immune
KEYTRUDA Working with your immune system to help fight cancer www.fightcancer.co.nz CONTACT DETAILS Your Oncologist/Specialist Name Phone Phone (after hours) Your Specialist Nurse Name Phone Phone (after
More informationPolicy. Medical Policy Manual Approved Revised: Do Not Implement Until 3/2/19. Nivolumab (Intravenous)
Nivolumab (Intravenous) NDC CODE(S) 00003-3772-XX Opdivo 40 MG/4ML SOLN (B-M SQUIBB U.S. (PRIMARY CARE)) 00003-3774-XX Opdivo 100 MG/10ML SOLN (B-M SQUIBB U.S. (PRIMARY CARE)) 00003-3734-XX Opdivo 240
More informationOpdivo. Opdivo (nivolumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.53 Subsection: Antineoplastic nts Original Policy Date: January 16, 2015 Subject: Opdivo Page: 1 of
More informationCENTENE PHARMACY AND THERAPEUTICS DRUG REVIEW 3Q17 April May
BRAND NAME Keytruda GENERIC NAME Pembrolizumab MANUFACTURER Merck & Co., Inc. DATE OF APPROVAL Non-small cell lung cancer (NSCLC) indication: May 10, 2017 Urothelial carcinoma indication: May 18, 2017
More informationPembrolizumab 200mg Monotherapy
Pembrolizumab 200mg This regimen supercedes NCCP Regimen 00347 Pembrolizumab 2mg/kg as of September 2018 due to a change in the licensed dosing posology. INDICATIONS FOR USE: INDICATION ICD10 Regimen Code
More informationPEMBROLIZUMAB (KEYTRUDA ) for the treatment of advanced melanoma or previously treated NSCLC
DRUG ADMINISTRATION SCHEDULE Day Drug Dose Route Diluent Rate Day 1 Pembrolizumab 2mg/kg IV Infusion 100mL 0.9% Sodium Chloride* Or 100mL 5% Glucose* *Final concentration must be between 1 to 10mg/mL Over
More informationMay 31, NCCN Guidelines: T-Cell Lymphomas
May 31, 2017 Maria Rivas, MD Senior Vice-President Global Medical Affairs Merck & Co. Kenilworth - Galloping Hill, +1 908 740 6533 K6-1624G maria.rivas1@merck.com NCCN Guidelines: T-Cell Lymphomas On behalf
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Portrazza) Reference Number: CP.PHAR.320 Effective Date: 03.01.17 Last Review Date: 11.18 Line of Business: Medicaid, HIM-Medical Benefit Coding Implications Revision Log See Important
More informationClinical Policy: Imatinib (Gleevec) Reference Number: CP.PHAR.65 Effective Date: Last Review Date: Line of Business: Oregon Health Plan
Clinical Policy: (Gleevec) Reference Number: CP.PHAR.65 Effective Date: 07.01.18 Last Review Date: 05.18 Line of Business: Oregon Health Plan Revision Log See Important Reminder at the end of this policy
More informationIMMUNOTHERAPY FOR THE TREATMENT OF LUNG CANCER
IMMUNOTHERAPY FOR THE TREATMENT OF LUNG CANCER A guide for patients and caregivers FREE TO BREATHE SUPPORT LINE (844) 835-4325 A FREE resource for lung cancer patients & caregivers About this brochure
More informationClinical Policy: Erlotinib (Tarceva) Reference Number: CP.PHAR74 Effective Date: Last Review Date: Line of Business: Oregon Health Plan
Clinical Policy: (Tarceva) Reference Number: CP.PHAR74 Effective Date: 07.01.18 Last Review Date: 02.18 Line of Business: Oregon Health Plan Revision Log See Important Reminder at the end of this policy
More informationATEZOLIZUMAB (TECENTRIQ )
DRUG ADMINISTRATION SCHEDULE Day Drug Daily Dose Route Diluent Rate Day 1 Atezolizumab 1200 mg IV Infusion 250mL 0.9% Sodium Chloride Over 60 minutes* *The initial dose of atezolizumab must be administered
More informationTechnology appraisal guidance Published: 18 July 2018 nice.org.uk/guidance/ta531
Pembrolizumab for untreated PD- L1-positive metastatic non-small-cell lung cancer Technology appraisal guidance Published: 18 July 2018 nice.org.uk/guidance/ta531 NICE 2018. All rights reserved. Subject
More informationKEYTRUDA (pembrolizumab) for injection, for intravenous use KEYTRUDA (pembrolizumab) injection, for intravenous use Initial U.S.
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use KEYTRUDA safely and effectively. See full prescribing information for KEYTRUDA. KEYTRUDA (pembrolizumab)
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Kadcyla) Reference Number: CP.PHAR.229 Effective Date: 06.01.16 Last Review Date: 05.18 Line of Business: Commercial, HIM-Medical Benefit, Medicaid Coding Implications Revision Log See
More informationITS MATCH MAY HAVE MET YOUR METASTATIC COLORECTAL CANCER. Important Safety Information. Indication and Limitation of Use. Your Doctor Discussion Guide
YOUR METASTATIC COLORECTAL CANCER MAY HAVE MET ITS MATCH There are different types of metastatic colorectal cancer (mcrc). If a RAS test shows your mcrc is wild-type RAS, Vectibix may help you live longer.
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Lartruvo) Reference Number: CP.PHAR.326 Effective Date: 03.01.17 Last Review Date: 11.18 Line of Business: Medicaid, HIM-Medical Benefit Coding Implications Revision Log See Important
More informationName of Policy: Yervoy (Ipilimumab)
Name of Policy: Yervoy (Ipilimumab) Policy #: 335 Latest Review Date: October 2013 Category: Pharmacology Policy Grade: A Background/Definitions: As a general rule, benefits are payable under Blue Cross
More informationClinical Policy: Pertuzumab (Perjeta) Reference Number: CP.PHAR.227 Effective Date: Last Review Date: Line of Business: HIM, Medicaid
Clinical Policy: (Perjeta) Reference Number: CP.PHAR.227 Effective Date: 06.01.16 Last Review Date: 05.18 Line of Business: HIM, Medicaid Coding Implications Revision Log See Important Reminder at the
More informationCLINICAL MEDICATION POLICY
CLINICAL MEDICATION POLICY Policy Name: Opdivo (nivolumab) injection Policy Number: Approved By: Medical Management, Clinical Pharmacy Products: Highmark Health Options Application: All participating hospitals
More informationClinical Policy: Trabectedin (Yondelis) Reference Number: CP.PHAR.204 Effective Date: Last Review Date: Line of Business: Medicaid
Clinical Policy: (Yondelis) Reference Number: CP.PHAR.204 Effective Date: 05.01.16 Last Review Date: 02.18 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end
More informationPembrolizumab in combination with epacadostat for unresectable or metastatic melanoma
NIHR Innovation Observatory Evidence Briefing: January 2018 Pembrolizumab in combination with epacadostat for unresectable or metastatic melanoma NIHRIO (HSRIC) ID: 7812 NICE ID: 9396 LAY SUMMARY Melanoma
More informationGeneral Information, efficacy and safety data
Horizon Scanning in Oncology Horizon Scanning in Oncology 23 rd Prioritization 2 nd quarter 2015 General Information, efficacy and safety data Eleen Rothschedl Anna Nachtnebel Priorisierung XXIII HSS Onkologie
More informationClinical Policy: Darbepoetin alfa (Aranesp) Reference Number: ERX.SPMN.13
Clinical Policy: (Aranesp) Reference Number: ERX.SPMN.13 Effective Date: 10/16 Last Review Date: 09/16 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationNewest Oncology Agents: PD 1 Inhibitors Clinical Information and Patient Management
Newest Oncology Agents: PD 1 Inhibitors Clinical Information and Patient Management Stacey Jassey Megan Brafford David Kwasny This CE activity was originally presented live at the 2015 NASP Annual Meeting
More informationWARNING, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS,
Celgene Corporation 86 Morris Avenue Summit, New Jersey 07901 Tel 908-673-9000 Fax 908-673-9001 October 2012 NEW Indication Announcement for ABRAXANE for Injectable Suspension (paclitaxel protein-bound
More informationClinical Policy: Brentuximab Vedotin (Adcetris) Reference Number: CP.PHAR.303
Clinical Policy: (Adcetris) Reference Number: CP.PHAR.303 Effective Date: 02/17 Last Review Date: 02/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Bosulif) Reference Number: CP.PHAR.105 Effective Date: 10.01.12 Last Review Date: 05.18 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of this
More informationCLINICAL MEDICAL POLICY
Policy Name: Policy Number: Approved By: Provider Notice Date: CLINICAL MEDICAL POLICY Portrazza (Necitumumab) MP-021-MD-WV Medical Management Original Effective Date: 06/02/2016 Annual Approval Date:
More informationClinical Policy: Dabrafenib (Tafinlar) Reference Number: CP.PHAR.239 Effective Date: 07/16 Last Review Date: 07/17 Line of Business: Medicaid
Clinical Policy: (Tafinlar) Reference Number: CP.PHAR.239 Effective Date: 07/16 Last Review Date: 07/17 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end of
More informationWhat You Need to Know About Lung Cancer Immunotherapy
What You Need to Know About Lung Cancer Immunotherapy Lung.org/immunotherapy What is immunotherapy? Immunotherapy for cancer, sometimes called immune-oncology, is a type of medicine that treats cancer
More informationCLINICAL MEDICAL POLICY
CLINICAL MEDICAL POLICY Policy Name: Faslodex (fulvestrant) Policy Number: MP-044-MD-DE Responsible Department(s): Medical Management; Clinical Pharmacy Provider Notice Date: 10/01/2017 Original Effective
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Brigatinib (Alunbrig) Reference Number: CP.PHAR.342 Effective Date: 07.17.17 Last Review Date: 05.18 Line of Business: Commercial; Medicaid Revision Log See Important Reminder at the end
More informationMEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 10/04/17 SECTION: DRUGS LAST REVIEW DATE: LAST CRITERIA REVISION DATE: ARCHIVE DATE:
BAVENCIO (avelumab) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More informationGLOBAL REGISTRATION STRATEGIES:
GLOBAL REGISTRATION STRATEGIES: Therapeutic Product (TP) and the Companion Diagnostic (CDx) Erin Pedalino Regulatory Affairs International MSD Unique Role as CDx Regulatory Liaison at a Therapeutic Product
More informationClinical Policy: Desmopressin Acetate (DDAVP Injection) Reference Number: CP.PHAR.214
Clinical Policy: Acetate (DDAVP Injection) Reference Number: CP.PHAR.214 Effective Date: 05/16 Last Review Date: 05/17 See Important Reminder at the end of this policy for important regulatory and legal
More informationNCCP Chemotherapy Regimen
INDICATIONS FOR USE: Pembrolizumab 2mg/kg INDICATION ICD10 Regimen Code *Reimbursement Status First line monotherapy for the treatment of advanced (unresectable or C43 00347a ODMS metastatic) melanoma
More informationUnderstanding your treatment and the side effects you may experience
Understanding your treatment and the side effects you may experience What does treat? is a prescription medicine used in combination with YERVOY to treat a type of skin cancer called melanoma that has
More informationClinical Policy: Temozolomide (Temodar) Reference Number: ERX.SPA.138 Effective Date:
Clinical Policy: (Temodar) Reference Number: ERX.SPA.138 Effective Date: 03.01.14 Last Review Date: 05.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationClinical Policy: Aprepitant (Emend) Reference Number: CP.PMN.19 Effective Date: 11/06 Last Review Date: 08/17
Clinical Policy: (Emend) Reference Number: CP.PMN.19 Effective Date: 11/06 Last Review Date: 08/17 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationKEYTRUDA (pembrolizumab) for injection, for intravenous use KEYTRUDA (pembrolizumab) injection, for intravenous use Initial U.S.
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use safely and effectively. See full prescribing information for. (pembrolizumab) for injection, for
More informationKEYTRUDA (pembrolizumab) for injection, for intravenous use KEYTRUDA (pembrolizumab) injection, for intravenous use Initial U.S.
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use safely and effectively. See full prescribing information for. (pembrolizumab) for injection, for
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Pembrolizumab (Keytruda) Reference Number: CP.PHAR.322 Effective Date: 07.01.18 Last Review Date: 11.17 Line of Business: Oregon Health Plan Revision Log See Important Reminder at the
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Tafinlar) Reference Number: CP.PHAR.239 Effective Date: 11.16.16 Last Review Date: 08.18 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of
More informationFDA Approved Indication(s) Firmagon is indicated for treatment of advanced prostate cancer.
Clinical Policy: (Firmagon) Reference Number: CP.PHAR.170 Effective Date: 10.01.16 Last Review Date: 11.17 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end
More informationClinical Policy: Bevacizumab (Avastin) Reference Number: ERX.SPMN.127
Clinical Policy: (Avastin) Reference Number: ERX.SPMN.127 Effective Date: 03/14 Last Review Date: 09/16 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Nerlynx) Reference Number: CP.PHAR.365 Effective Date: 09.05.17 Last Review Date: 11.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Stivarga) Reference Number: CP.PHAR.107 Effective Date: 12.01.12 Last Review Date: 05.18 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Iressa) Reference Number: CP.PHAR.68 Effective Date: 11.16.16 Last Review Date: 11.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Erbitux) Reference Number: CP.PHAR.317 Effective Date: 02.01.17 Last Review Date: 11.18 Line of Business: Commercial, HIM, Medicaid Coding Implications Revision Log See Important Reminder
More informationAlimta (pemetrexed) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage
Alimta (pemetrexed) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 09/01/2007 Current Effective Date: TBD003/01/201703/01/2018 POLICY A. INDICATIONS The indications
More informationClinical Policy: Pralatrexate (Folotyn) Reference Number: CP.PHAR.313 Effective Date: Last Review Date: Line of Business: Medicaid
Clinical Policy: (Folotyn) Reference Number: CP.PHAR.313 Effective Date: 02.01.17 Last Review Date: 11.17 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end of
More informationClinical Policy: Panitumumab (Vectibix) Reference Number: CP.PHAR.321
Clinical Policy: (Vectibix) Reference Number: CP.PHAR.321 Effective Date: 03/17 Last Review Date: 03/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Sandostatin, Sandostatin LAR Depot) Reference Number: CP.PHAR.40 Effective Date: 03.01.10 Last Review Date: 02.18 Line of Business: Commercial, Medicaid Coding Implications Revision Log
More informationKEYTRUDA (pembrolizumab) for injection, for intravenous use KEYTRUDA (pembrolizumab) injection, for intravenous use Initial U.S.
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use safely and effectively. See full prescribing information for. (pembrolizumab) for injection, for
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Darbepoetin Alfa (Aranesp) Reference Number: CP.PHAR.236 Effective Date: 06.01.16 Last Review Date: 05.18 Line of Business: HIM, Medicaid Coding Implications Revision Log See Important
More informationMerck Announces FDA Approval of KEYTRUDA. Provided to Investors as a Reference
Merck Announces FDA Approval of KEYTRUDA Provided to Investors as a Reference Forward-Looking Statement This presentation includes forward-looking statements within the meaning of the safe harbor provisions
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Mekinist) Reference Number: CP.PHAR.240 Effective Date: 07.01.16 Last Review Date: 08.18 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of
More informationCLINICAL MEDICAL POLICY
CLINICAL MEDICAL POLICY Policy Name: Avastin (bevacizumab) Policy Number: MP-030-MD-DE Responsible Department(s): Medical Management; Clinical Pharmacy Provider Notice Date: 10/01/2017 Original Effective
More informationNon-Small Cell Lung Cancer:
Non-Small Cell Lung Cancer: Where We Are Today Sila Shalhoub, PharmD PGY2 Oncology Pharmacy Resident Shalhoub.Sila@mayo.edu Pharmacy Grand Rounds September 26, 2017 2017 MFMER slide-1 Objectives Identify
More informationImfinzi (durvalumab) (Intravenous)
Imfinzi (durvalumab) (Intravenous) Last Review Date: 09/05/2018 Date of Origin: 05/30/2017 Dates Reviewed: 05/2017, 08/2017, 11/2017, 02/2018, 05/2018, 09/2018 Document Number: IC-0301 I. Length of Authorization
More informationTechnology appraisal guidance Published: 7 October 2015 nice.org.uk/guidance/ta357
Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab Technology appraisal guidance Published: 7 October 2015 nice.org.uk/guidance/ta357 NICE 2018. All rights reserved.
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Lynparza) Reference Number: CP.PHAR.360 Effective Date: 10.03.17 Last Review Date: 02.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this
More informationITS MATCH MAY HAVE MET YOUR METASTATIC COLORECTAL CANCER. What to expect during treatment with Vectibix. Important Safety Information.
YOUR METASTATIC COLORECTAL CANCER MAY HAVE MET ITS MATCH In a clinical study of wild-type RAS metastatic colorectal cancer, Vectibix + FOLFOX helped patients live longer than FOLFOX alone (25.8 months
More informationIMMUNOTHERAPY FOR THE TREATMENT OF LUNG CANCER
IMMUNOTHERAPY FOR THE TREATMENT OF LUNG CANCER A guide for patients and caregivers TM Content is consistent with the Oncology Nursing Society Standards and Guidelines. The ONS Seal of Approval does not
More informationform: Concentrate for solution for infusion. intravenous push or bolus injection. not been previously treated with chemotherapy. Inclusion criteria
Product Name KEYTRUDA Active substance Pembrolizumab Medical Need Program with KEYTRUDA for the First Line treatment of metastatic Non Small Cell Lung Cancer (NSCLC) in adults whose tumors express PD L1
More informationTecentriq. Tecentriq (atezolizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.80 Subject: Tecentriq Page: 1 of 5 Last Review Date: September 15, 2017 Tecentriq Description Tecentriq
More informationClinical Policy: Pertuzumab (Perjeta) Reference Number: ERX.SPMN.94
Clinical Policy: (Perjeta) Reference Number: ERX.SPMN.94 Effective Date: 07/16 Last Review Date: 06/16 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationThe road less travelled: what options are available for patients with advanced squamous cell carcinoma?
Robert Pirker Medical University of Vienna Vienna, Austria The road less travelled: what options are available for patients with advanced squamous cell carcinoma? Disclosures Honoraria for advisory board/consulting
More informationPrior Authorization Review Panel MCO Policy Submission
Prior Authorization Review Panel MCO Policy Submission A separate copy of this form must accompany each policy submitted for review. Policies submitted without this form will not be considered for review.
More informationFor the Patient: USMAVFIPI
For the Patient: USMAVFIPI Other Names: First-Line Treatment of Unresectable or Metastatic Melanoma Using Ipilimumab U = Undesignated (requires special request) SM = Skin and Melanoma AV = Advanced F =
More information